Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial
Journal
European journal of cancer (Oxford, England : 1990)
Journal Volume
168
Pages
91
Date Issued
2022-06
Author(s)
Freemantle, Nick
Mollon, Patrick
Meyer, Tim
El-Khoueiry, Anthony B
Kelley, Robin K
Baron, Ari D
Benzaghou, Fawzi
Mangeshkar, Milan
Abou-Alfa, Ghassan K
Abstract
The CELESTIAL trial (NCT01908426) demonstrated overall survival benefit for cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (aHCC) who had received prior sorafenib treatment. This analysis of CELESTIAL compared the impact of cabozantinib versus placebo on health-related quality of life (HRQoL).
Subjects
Cabozantinib; Carcinoma; Hepatocellular; Liver neoplasms; Patient Reported Outcome Measures; Patient health questionnaire; Quality-adjusted life years; Visual analog scale
SDGs
Publisher
ELSEVIER SCI LTD
Type
journal article